Alexion Pharmaceuticals’ ravulizumab has expanded the range of indications for treating a rare complement-mediated disease.
Regulatory
Actions of government agencies regulating the pharmaceutical industry: approval, rejection, and prohibition of drugs, granting special statuses.
Posted inMetabolism, New Drugs, Regulatory
Wegovy: Most Effective Drug for Weight Loss
Semaglutide can help you lose 15% of your excess weight in a year. And even more.
Posted inAutoimmune Diseases, Neuroscience, New Drugs, Regulatory
Kesimpta: Highly Effective New Drug for Multiple Sclerosis
Ofatumumab by Novartis is as good and convenient as Ocrevus by Roche against multiple sclerosis.
Posted inNeuroscience, New Drugs, Regulatory
Lybalvi: New Drug for Schizophrenia and Bipolar I Disorder
Combination of olanzapine and samidorphan will prevent unwanted weight gain in patients.
Posted inAutoimmune Diseases, New Drugs, Regulatory
Zeposia: New Drug for Ulcerative Colitis
Oral ozanimod will provide clinical remission of ulcerative colitis for a third of patients.
Posted inAutoimmune Diseases, New Drugs, Rare/Orphan Diseases, Regulatory
Empaveli: Powerful New Drug for Paroxysmal Nocturnal Hemoglobinuria
Pegcetacoplan is more effective in treating paroxysmal nocturnal hemoglobinuria compared to Soliris.
Posted inAutoimmune Diseases, Neuroscience, New Drugs, Regulatory
Ponvory: Another Drug for Multiple Sclerosis
Ponesimod is a new drug that changes the course of multiple sclerosis and is a direct competitor to Gilenya (fingolimod), Mayzent (siponimod), and Zeposia (ozanimod).